Brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce $88.02 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $84.15 million and the highest estimate coming in at $92.17 million. Supernus Pharmaceuticals reported sales of $62.37 million in the same quarter last year, which indicates a positive year over year growth rate of 41.1%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $88.02 million for the current fiscal year, with estimates ranging from $294.60 million to $305.98 million. For the next financial year, analysts anticipate that the company will post sales of $393.97 million per share, with estimates ranging from $385.13 million to $404.56 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. The business’s revenue was up 41.5% compared to the same quarter last year.
In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 165,750 shares of company stock valued at $7,133,973. 6.70% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Advisor Group Inc. lifted its position in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 410 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $188,000. Flinton Capital Management LLC lifted its position in Supernus Pharmaceuticals by 88.9% in the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock valued at $205,000 after purchasing an additional 2,240 shares during the last quarter. Balyasny Asset Management LLC bought a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $206,000. Finally, M&T Bank Corp bought a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $213,000. 98.71% of the stock is owned by institutional investors and hedge funds.
Supernus Pharmaceuticals (NASDAQ SUPN) opened at $38.40 on Tuesday. Supernus Pharmaceuticals has a twelve month low of $24.05 and a twelve month high of $50.04. The company has a market capitalization of $1,970.00, a PE ratio of 34.91 and a beta of 1.08.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.